Pharma News, 2022

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 20...

The FDA has granted a priority review to Takeda’s supplemental Biologics License Application (sBLA) for Takhzyro (lanadelumab-flyo) for prevention of attacks of hereditary edema in children under...

Eli Lilly has received FDA’s Fast Track designation for tirzepatide for treatment of adults with obesity or who are overweight with weight-related comorbidities. ...

The FDA has granted a Fast Track designation to Immutep’s eftilagimod alpha in combination with pembrolizumab for treatment of first-line nonsmall-cell lung cancer (NSCLC). ...

A bipartisan bill has been introduced in the US Congress that will try to block Centers for Medicare and Medicaid Services (CMS) restrictions on Biogen’s Alzheimer’s therapy Aduhelm being exten...

Cue Biopharma has received Fast Track designation from the FDA for its CUE-101 drug candidate for treatment of human papilloma virus recurrent/metastatic head and neck squamous cell carcinoma as a ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. ...

Vir Biotechnology received a multi-year contract from the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of a pre-exposure drug for influenza and other po...

The Nobel Prize in Chemistry 2022 was awarded jointly to Carolyn R. Bertozzi, Morten Meldal and K. Barry Sharpless "for the development of click chemistry and bioorthogonal chemistry". ...

UK-based Myovant Sciences has rejected a $2.5 billion takeover bid from Sumitovant Biopharma and its parent company Sumitomo Pharma.

Santhera Pharmaceuticals has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for its investigational drug vamorolone for treatment of patients with Duc...

Otsuka subsidiary Taiho Oncology has gained an accelerated approval from the FDA for its Lytgobi (futibatinib) tablets for treatment of adult patients with previously treated, unresectable, locally...